Literature DB >> 15576020

Effect of acidic ternary compounds on the formation of miconazole/cyclodextrin inclusion complexes by means of supercritical carbon dioxide.

Valéry Barillaro1, Pascal Bertholet, Sandrine Henry de Hassonville, Eric Ziemon, Brigette Evrard, Luc Delattre, Géraldine Piel.   

Abstract

PURPOSE: The aim of the study is to evaluate the effect of different acidic compounds on the inclusion of miconazole (MICO) in several cyclodextrins (CDs) using supercritical carbon dioxide (SCCO(2) ) processing.
METHODS: Physical mixtures were processed by SCCO(2) at 30 MPa, 125 degrees C during 60 minutes in a static mode to produce inclusion complexes. The inclusion complexes were characterized by differential solubility, Fourier transform infrared spectroscopy (FT-IR) and dissolution test.
RESULTS: The best inclusion yields were achieved with the combination of MICO base and HPgammaCD with or without acids. Maleic and fumaric acids influenced the MICO inclusion differently in function of their conformation. During the process, a miconazole salt was observed with maleic acid and characterized by thermal analysis and mass spectrometry. The kinetics inclusion followed a saturation-type shape curve. FT-IR confirmed the presence of genuine inclusion complexes. The complexes MICO base/HPgammaCD/(L-tartaric acid) enhanced the dissolution rates of MICO more than the corresponding physical mixtures did. Lastly, the stability study revealed that the complexes were stable.
CONCLUSIONS: The formation of stable complexes between MICO and CDs is possible using SCCO(2). Moreover an acidic ternary compound is able to modify the formation of the complex. The inclusion complexes, which show better dissolution profiles than those with the corresponding physical mixtures, could lead to an increase of the oral bioavailability of MICO.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576020

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  7 in total

1.  Composition optimization and stability testing of a parenteral antifungal solution based on a ternary solvent system.

Authors:  Kristóf Kovács; István Antal; György Stampf; Imre Klebovich; Krisztina Ludányi
Journal:  AAPS PharmSciTech       Date:  2010-02-24       Impact factor: 3.246

2.  Oral bioavailability in pigs of a miconazole/hydroxypropyl-gamma-cyclodextrin/L-tartaric acid inclusion complex produced by supercritical carbon dioxide processing.

Authors:  Valéry Barillaro; Brigitte Evrard; Luc Delattre; Géraldine Piell
Journal:  AAPS J       Date:  2005-08-18       Impact factor: 4.009

3.  Miconazole nitrate oral disintegrating tablets: in vivo performance and stability study.

Authors:  Tarek A Ahmed; Khalid M El-Say; Maged F Mahmoud; Ahmed M Samy; Alia A Badawi
Journal:  AAPS PharmSciTech       Date:  2012-05-15       Impact factor: 3.246

4.  Preparation and in vitro/in vivo characterization of porous sublingual tablets containing ternary kneaded solid system of vinpocetine with î-cyclodextrin and hydroxy Acid.

Authors:  Mona H Aburahma; Hanan M El-Laithy; Yassin El-Said Hamza
Journal:  Sci Pharm       Date:  2010-05-17

5.  Crystal structure changes of gamma-cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide.

Authors:  Tarja Toropainen; Teemu Heikkilä; Jukka Leppänen; Laura Matilainen; Sitaram Velaga; Pekka Jarho; Johan Carlfors; Vesa-Pekka Lehto; Tomi Järvinen; Kristiina Järvinen
Journal:  Pharm Res       Date:  2007-03-24       Impact factor: 4.580

Review 6.  Supercritical Fluid Technology: An Emphasis on Drug Delivery and Related Biomedical Applications.

Authors:  Ranjith Kumar Kankala; Yu Shrike Zhang; Shi-Bin Wang; Chia-Hung Lee; Ai-Zheng Chen
Journal:  Adv Healthc Mater       Date:  2017-07-28       Impact factor: 9.933

Review 7.  Supercritical Carbon Dioxide as a Green Alternative to Achieve Drug Complexation with Cyclodextrins.

Authors:  Mauro Banchero
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.